LINCOLNSHIRE, Ill. – Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for the third consecutive year. In addition to the certification, Nexus has been recognized as #19 on the list of Best...
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to...
I am writing with regards to the Opinion piece titled, “Our Drug Supply Is Sick. How Can We Fix It?” (Sept. 18, 2021). As the writer clearly highlights, the U.S. generic pharmaceutical industry is facing a crisis. Our company, Nexus Pharmaceuticals, Inc., is leading...
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first...
PLEASANT PRAIRIE, Wis.–(BUSINESS WIRE)–On Friday, July 16, 2021, Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, celebrated the opening of Project Tomorrow—the company’s new, state-of-the-art...
Milwaukee, June 21, 2021 – The Medical College of Wisconsin (MCW) School of Pharmacy partnered with Nexus Pharmaceuticals, Inc. for a pharmaceutical clinical-use study to compare the use of EMERPHED™, a ready-to-use (RTU) ephedrine sulfate product, to the...
